ImmunoServ Awarded Innovate UK Funding to Develop First Standardised T Cell Immunity Test for Group A Streptococcus

The test, known as Strep A Immuno-T™, will make it easier to measure how well an individual’s immune system, specifically T cells, responds to Strep A. This is an important step towards developing effective vaccines and new tools to fight serious Strep A-related diseases such as rheumatic heart disease, kidney damage, and toxic shock syndrome.

“This funding from Innovate UK is a vital boost in our mission to develop immunity testing that supports better vaccine development and public health strategies,” said Dr Martin Scurr, Chief Scientific Officer, ImmunoServ. “We’re excited to build on the success of our COVID-19 Immuno-T platform and bring this innovation to a critically underserved area.”

T cells are a key part of the body’s defence system against bacteria and viruses. But until now, testing T cell responses has required expensive, complex lab work. The Strep A Immuno-T, using a simplified whole blood method, will enable standardised and scalable testing, making it accessible beyond specialist research labs.

This project will support the test’s optimisation for upcoming human challenge studies performed by project collaborators in Australia and The Gambia, and prepare it for wider adoption by vaccine developers and public health bodies in the UK and globally.

#BiomedicalCatalyst #StrepAImmunoT #InnovateUKFunded

Read more about the Biomedical Catalyst funding here:

Biomedical Catalyst funding gives boost to healthcare innovation – Innovate UK Business Connect